Streamling "Library-to-Lead" for your Antibody Therapeutics - 25

Antibody
Characterization Balances
Rigor and Reason
Emphasizes a Combination of AntibodyDependent and -Independent Testing Methods
Angelo DePalma, Ph.D.

Antibodies are critical research reagents,
25

| GENengnews.com

says Nicolas Schrantz, Ph.D., senior manager
for antibody development at Thermo Fisher
Scientific. They can lead to research success,
but only if they perform as desired-which
is to say, as advertised. "Developing an antibody that recognizes the correct target
using a specific application is an art that
requires scientific knowledge and technical
expertise," notes Dr. Schrantz. "Unfortunately,
many antibodies on the market that claim to
have been validated for a specific application
simply do not recognize the target they are

ADDITIONAL CONTENT

Application Note
Multi-Parameter Epitope-Centric Data Used to
Elucidate Mechanisms of Action of Antibodies
Learn how high throughput epitope binning assays can
achieve exquisite epitope resolution of your antibody
library and improve your drug discovery efforts.

Download PDF

®

Morsa Images / Getty Images

A

uthentication is becoming a hot-button
topic among researchers. For example,
researchers who use cells that are meant to
possess distinct characteristics have been
making an issue of cell-line authentication.1
With increasing frequency, researchers who
use antibodies are raising authentication
concerns of their own. These researchers
are insistent that antibodies be validated
for function and purpose.


https://info.carterra-bio.com/hubfs/Downloads/Carterra%20App%20Note%20%E2%80%93%20mAb%20Mechanism%20of%20Action.pdf http://www.GENengnews.com

Streamling "Library-to-Lead" for your Antibody Therapeutics

Table of Contents for the Digital Edition of Streamling "Library-to-Lead" for your Antibody Therapeutics

Contents
Streamling "Library-to-Lead" for your Antibody Therapeutics - 1
Streamling "Library-to-Lead" for your Antibody Therapeutics - 2
Streamling "Library-to-Lead" for your Antibody Therapeutics - 3
Streamling "Library-to-Lead" for your Antibody Therapeutics - Contents
Streamling "Library-to-Lead" for your Antibody Therapeutics - 5
Streamling "Library-to-Lead" for your Antibody Therapeutics - 6
Streamling "Library-to-Lead" for your Antibody Therapeutics - 7
Streamling "Library-to-Lead" for your Antibody Therapeutics - 8
Streamling "Library-to-Lead" for your Antibody Therapeutics - 9
Streamling "Library-to-Lead" for your Antibody Therapeutics - 10
Streamling "Library-to-Lead" for your Antibody Therapeutics - 11
Streamling "Library-to-Lead" for your Antibody Therapeutics - 12
Streamling "Library-to-Lead" for your Antibody Therapeutics - 13
Streamling "Library-to-Lead" for your Antibody Therapeutics - 14
Streamling "Library-to-Lead" for your Antibody Therapeutics - 15
Streamling "Library-to-Lead" for your Antibody Therapeutics - 16
Streamling "Library-to-Lead" for your Antibody Therapeutics - 17
Streamling "Library-to-Lead" for your Antibody Therapeutics - 18
Streamling "Library-to-Lead" for your Antibody Therapeutics - 19
Streamling "Library-to-Lead" for your Antibody Therapeutics - 20
Streamling "Library-to-Lead" for your Antibody Therapeutics - 21
Streamling "Library-to-Lead" for your Antibody Therapeutics - 22
Streamling "Library-to-Lead" for your Antibody Therapeutics - 23
Streamling "Library-to-Lead" for your Antibody Therapeutics - 24
Streamling "Library-to-Lead" for your Antibody Therapeutics - 25
Streamling "Library-to-Lead" for your Antibody Therapeutics - 26
Streamling "Library-to-Lead" for your Antibody Therapeutics - 27
Streamling "Library-to-Lead" for your Antibody Therapeutics - 28
Streamling "Library-to-Lead" for your Antibody Therapeutics - 29
Streamling "Library-to-Lead" for your Antibody Therapeutics - 30
Streamling "Library-to-Lead" for your Antibody Therapeutics - 31
Streamling "Library-to-Lead" for your Antibody Therapeutics - 32
https://www.nxtbookmedia.com